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Abstract: Background: Real-life data on the use of pirfenidone and 
nintedanib to treat patients with idiopathic pulmonary fibrosis (IPF) are 
still scarce. 
Methods: We compared the efficacy of either pirfenidone (n=78) or 
nintedanib (n=28) delivered over a 24-month period in patients with IPF, 
followed at two regional clinic centers in Italy, with a group of 
patients who refused the treatment (n=36), and who were considered to be 
controls.  All patients completed regular visits at 1- to 3-month 
intervals, where primary [forced vital capacity (FVC) and diffusing 
capacity of the lungs for carbon monoxide (DLCO)] and secondary outcomes 
(side effects, treatment compliance, and mortality) were recorded. 
Results: Over time, the decline in FVC and DLCO was significantly higher 
(p=0.0053 and p=0.037, respectively) in controls when compared with the 
combined treated group, with no significant difference between the two 
treated groups. Compared to patients with less advanced disease (GAP 
(Gender, Age, Physiology) stage I), those in GAP stages II and III showed 
a significantly higher decline in both FVC and DLCO irrespective of the 
drug taken. Side effects were similarly reported in patients receiving 
pirfenidone and nintedanib (5% and 7%, respectively), whereas mortality 
did not differ among the three groups. 
Conclusion: This real-life study demonstrated that both pirfenidone and 
nintedanib were equally effective in reducing the decline of FVC and DLCO 
versus non-treated patients after 24 months of treatment; however, 
patients with more advanced disease were likely to show a more rapid 
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We thank the Reviewer for the precise reviewing process of our work. We have welcomed all of her/his 
comments and we have tried to emend the manuscript accordingly.  
 
Major comments 
Reviewer 1’s comment 1 
Did the authors calculate the power of the study (e.g. number of patients needed to respond to the main 
aim) before its start? This does not seem to be mentioned along the paper. 
Answer to Reviewer 1’s comment 1 
We thank the Reviewer for this comment. We did not perform a sample size calculation on primary 
outcome due to the nature and purpose of the study that aims at exploring the real life local experience of 
two referral center for IPF drugs prescription. We admit that this limitation has surely underpowered the 
results of the study and add it in the dedicate section.  
 
Reviewer 1’s comment 2 
There is no any information on what kind of treatment the control patients had. Anyone? Others than 
pirfenidone and nintedanib? 
Answer to Reviewer 1’s comment 2 
We really thank the Reviewer for this comment that gave us the chance to better illustrate this point. For 
those patients refusing the treatment, we only provide symptom support, as needed (i.e. oxygen, HFNC, 
opioids etc). This was added in the Methods section: “Their “chronic” therapy, for any other comorbidity 
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was left unchanged; symptomatic intervention for dyspnea was prescribed when needed (i.e. opioids, High 
Flow Nasal Cannula or Oxygen”. 
 
Reviewer 1’s comment 3 
Discussion: the whole discussion requires editing and revision. The first 4 paragraphs at page 9 could be in 
part removed and in part moved to the Introduction. Discussion should better start by highlighting the 
results and the novelty of the results, what this paper adds to the known literature. Page 10: "Interestingly 
our study confirms some results of the previous ones…". References are needed. Discussion of the present 
results and those from the main RCT should be added. 
Answer to Reviewer 1’s comment 3 
We agree with the Reviewer with this comment. We have thus extensively modified the Discussion section, 
as suggested.  
 
Reviewer 1’s comment 4 
Figure 1 and Figure 2: statistical significance is missing into the figures. Figure 1 and Figure 2 seem to report 
data on patients with GAP Index 1?  From the text the reader understands that they refer to all patients, 
this must be clarified. 
Answer to Reviewer 1’s comment 4 
We thank the Reviewer for this comment and we do apologize for the mistaken figure presented. We have 
now produced the correctly formatted figure and we have added the p values as indicated. Figures 1 and 2 
now refer to all patients. This has been now clarified: Figure 1 and 2 illustrate the time course of FVC and 
DLCO respectively, irrespective of the GAP index, during the 24 months time period. 
 
Reviewer 1’s comment 5 
Table 1 and Table 2: IPF not treated should better be in the 3rd column. 
Answer to Reviewer 1’s comment 5 
We thank the Reviewer for this comment. We have emended the table as indicated.   
 
 
Reviewer 1’s comment 6 
Table 2: Were side effects statistically different? 
Answer to Reviewer 1’s comment 6 
We thank the Reviewer for this comment. No statistical differences were found. This was added in the text 




Reviewer 1’s comment 7 
The whole text of the paper generally should benefit of a revision/editing of the English. 
Answer to Reviewer 1’s comment 7 
We thank the Reviewer for this suggestion. The manuscript has been edited by a professional, native 
English-speaking editor with 25 years' experience editing medical and science manuscripts (see in 
acknowledgments). 
  
Reviewer 1’s comment 8 
The abstract should mention which are the main and secondary aims of the study. 
Answer to Reviewer 1’s comment 8 
We thank the Reviewer for this suggestion. We have thus modified the abstract and indicated primary and 
secondary outcomes: “All completed regular visits at 1-to 3-month intervals, where primary [forced vital 
capacity (FVC) and diffusing lung capacity (DLCO)] and secondary outcomes (side effects, treatment 
compliance, and mortality) were recorded”. 
 
Reviewer 1’s comment 9 
Page 4, line 2: ".. with IPF based on.." should better read as ".. with IPF diagnosis based on..". 
Answer to Reviewer 1’s comment 9 
We thank the Reviewer for this comment. We modified the manuscript accordingly. 
 
Reviewer 1’s comment 10 
Page 4, lines 3: "Patients were naïve to one of the two drugs.." should better read as "Patients were naïve 
from both the 2 drugs tested". 
Answer to Reviewer 1’s comment 10 
We thank the Reviewer for this comment. We modified the manuscript accordingly. 
 
Reviewer 1’s comment 11 
Page 4, 2nd paragraph: the authors should explain that the mentioned criteria were the criteria requested 
for starting an anti-IPF treatment, as the reader can guess. 
Answer to Reviewer 1’s comment 11 
We thank the Reviewer for this comment with which we agree. We have now better specified the issue 
(According to the Italian Health Ministry rule, criteria for starting an anti-IPF treatment were) 
 
Reviewer 1’s comment 12 
 4 
Page 4, last paragraph: "The authorization to prescribe pirfenidone in Italy was…" - was this in the context 
of a clinical study? Authors should better explain this. 
Answer to Reviewer 1’s comment 12 
We thank the Reviewer for this comment. We have modified the manuscript as follows: “In Italy, at least in 
the first few years (depending on the geographical location) of release of Pirfenidone or Nintedanib, the 
local Health Care Agency, required its specific authorization to start the anti-IPF treatment in all the 
patients. All patients signed informed consent to enter the present study”. 
 
Reviewer 1’s comment 13 
Page 5, 3rd paragraph: "The control group of the study..". The whole paragraph is difficult to read, and 
would need some improvement. 
Answer to Reviewer 1’s comment 13 
We thank the Reviewer for this comment. We have modified the manuscript accordingly: “The control 
group of the study was composed by 36 IPF patients that after the initial clinical evaluation decided to 
refuse the proposed treatment with an anti-IPF drug or had a contraindication. Specifically, 13 were not 
eligible due to DLCO<30% (n=4), elevated age (n=5) or FVC>90% (n=4) (this limit was removed after May 
2016 by the local health agency). Eleven patients were not fully convinced by the effectiveness of the 
medication, mainly because lack of a clear effect on survival, 6 refused the anti-IPF treatment because of 
fear of side effects, 3 were not selected due to elevated value of alanine aminotransferase, aspartate 
aminotransferase or bilirubin, 2 dropped-out after few weeks (<12) of treatment, and 1 for unknown 
reason”. 
 
Reviewer 1’s comment 14 
Page 5, last paragraph: the authors say that the primary outcome was the trend of lung function - was this 
in terms of FVC and DLCO? This seems the case from the Tables and Figures but it is not mentioned along 
the text nor in the abstract. 
Answer to Reviewer 1’s comment 14 
We thank the Reviewer for this comment with which we agree. Both measurements were considered 
primary outcomes. This was now better specified in the abstract (see a previous point) and in the Results 
section. Figure 1, panel A shows the time course of FVC, irrespective of the GAP index, during the 24 month 
time period. A statistical significant reduction in this parameter was observed in the control group during 
the time course (p=0.0053); when compared to the pirfenidone and nintedanib groups the decline in the 
controls was statistically significant at months 12 and 24 (0.027 and 0.011 vs pirfenidone and 0.043 and 
0.036 vs nintedanib, respectively). 
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Figure 1, panel B illustrates the time course in the treated groups, irrespective of the GAP index, according 
to the drug taken, and no difference was observed during the time course for both treatment, as well as 
between the pirfenidone and nintedanib group.  
 
Reviewer 1’s comment 15 
Page 5, last line: ".. as determined through September 30, 2018" is not clear what it means. 
Answer to Reviewer 1’s comment 15 
We thank the Reviewer for this comment. We have now deleted that statement. 
 
Reviewer 1’s comment 16 
The recent retrospective observational multicentre study in Italian IPF patients (IRENE Study) by Vancheri C 
et al, 2019 should be cited, discussed and added amongst references. 
Answer to Reviewer 1’s comment 16 










We really thank the Reviewer for the careful reviewing of our work. We welcome all of her/his suggestions 
and we have tried to modify the manuscript accordingly. 
 
Reviewer 2’s comment 1 
Is FVC (pulmonary functions) decline not a surrogate marker of survival? Authors should describe more 
details. 
Answer to Reviewer 2’s comment 1 
We really thank the Reviewer for this comment that gave us the chance to better illustrate this point. It has 
been shown that the decline in this parameter is associated with survival, but defining it surrogate it may 
be a bit misleading, since death in these patients may be also related to other factors, such as co-
morbidities, invasive procedure or infectious complications. This has been discussed in the text. 
 
Reviewer 2’s comment 2 
Baseline %FVC seems to be different among three groups in Figure 1. Authors should consider 'adjusted 
analysis of %FVC at baseline'. 
Answer to Reviewer 2’s comment 2 
We thank the Reviewer for this comment with which we agree. Indeed absolute % value of FVC at baseline 
actually differs among groups (as now indicated in Table 1). However after having performed adjusted 
analysis for baseline %FVC as suggested no differences were observed among the 3 groups. This has been 
now better specified in text in the Results section. 
 
Reviewer 2’s comment 3 
Is there a difference between the baseline FVC of the deceased patient and the baseline FVC of the 
surviving patient? 
Answer to Reviewer 2’s comment 3 
We thank the Reviewer for this comment. We added the following sentence in the Results section: Both 
baseline value of FVC and the rate of FVC decline over time were not statistically different between survivors 
and non-survivors, irrespective of the groups. 
 
Reviewer 2’s comment 4 
Are DLco decline and FVC decline equally suppressed in the same patient?  If the two are separated, why? 
Answer to Reviewer 2’s comment 4 
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We thank the Reviewer for this question that strikes an interesting point. We did a statistical analysis on 
this point, and the two trends during the time course paralleled. This was added in the text (The changes in 
FVC and DLCO closely paralleled over time in the 3 groups). 
 
Reviewer 2’s comment 5 
List all causes of death. 
Answer to Reviewer 2’s comment 5 
We have appreciated the Reviewer’s comment. As we stated previously in the text, we could only record 
the cause of death in those patients dying in the hospital, now shown on table 3. A telephone interview 
was done regularly to assess whether a patients was still alive or not. The cause of death reported from the 
family or surrogates were not often clear, and these data are usually not considered in the clinical studies, 
due to lack of reliability. We reported the “reliable cause” in the Methods and Results (Causes of death 
were recorded only when this occurred in the hospital. A telephone interview was done regularly to assess 
whether a patients was still alive or not. The cause of death reported from the family or surrogates were 
not often clear, and these data are usually not considered in the clinical studies, due to lack of reliability) 
(Table 3 shows the hospital cause of death in 3 groups. Data recorded during the telephone interview were 
not considered reliable). 
 
Reviewer 2’s comment 6 
The 24 months observation period is expected to involve various prognostic factors other than 'IPF 
progression'. In Table 1, cardiovascular comorbidities are more in the non-treatment group. Is there any 
effect on the cause of death? 
Answer to Reviewer 2’s comment 6 
We thank the Reviewer for this comment. Being the cause of death not always certain we could not provide 
a clear answer (see Answer to Reviewer 2’s comment 5). 
 
Reviewer 2’s comment 7 
Even if there is a difference in FVC decline in the comparison of control vs anti-fibrotic group, the reason 
why there is no difference in all cause mortality may be due to other causes of death. I want you to add 
some consideration. 
Answer to Reviewer 2’s comment 7 
We thank the Reviewer for this comment with which we definitely agree. We have thus added a sentence 
about this important issue in the text. 
 
Reviewer 2’s comment 8 
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Nintenamib"? Isn't "Nintedanib" correct  
Answer to Reviewer 2’s comment 8 
We thank the Reviewer for this comment. We have corrected the manuscript accordingly.  
 
Reviewer 3 
We really thank the Reviewer for the careful reviewing of our work. We welcome all of her/his suggestions 
and we have tried to modify the manuscript accordingly. 
 
 
Reviewer 3’s comment 1 
Could you show us average exposure weeks of anti-fibrotic drugs in Table 1 ? 
Answer to Reviewer 3’s comment 1 
We thank the Reviewer for this question. All the enrolled patients underwent 24 months of treatment for 
the analysis of data. This has been clarified in the text. 
 
 
Reviewer 3’s comment 2 
Could you show information of clinical symptoms such as cough, dyspnea of each group in Table 1 ? 
Answer to Reviewer 3’s comment 2 
We thank the Reviewer for this question. We have added the baseline value of the requested data, since a 
systematic collection of these data was not performed at each visit. 
 
Reviewer 3’s comment 3 
Do you have information about acute exacerbation and lung cancer development of each group ? 
Answer to Reviewer 3’s comment 3 
We have appreciated the Reviewer’s question. Unfortunately it was very difficult to collect reliable data on 
exacerbations, especially for those patients living far from the hospital. We have however identified a clear 
picture of the occurrence of lung tumor. Data are reported in the Results section.  
 
 
Reviewer 3’s comment 4 
1.In Table 1, Line Age, you had better explain (number). 
Answer to Reviewer 3’s comment 4 
We thank the Reviewer for this comment. We have clarified number and percentage in Table 1. 
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Reviewer 3’s comment 5 
I think you had better include major functional parameters such as FVC and DLco in Table 1. 
Answer to Reviewer 3’s comment 5 
We thank the Reviewer for this comment. We have added the function parameters as requested. 
 
Reviewer 3’s comment 6 
3.You had better include mortality of each group in Table 1. 
Answer to Reviewer 3’s comment 6 




Reviewer 3’s comment 7 
Regarding side effects in Table 2, difficult in concentration is quite unusual adverse reaction in pirfenidone. 
How about the other drug contribution of this symptom ? 
Answer to Reviewer 3’s comment 7 
We thank the Reviewer for this comment. In the 3 patients who developed this symptom, no other drug 
was likely to induce the problem. We have added this in the manuscript. 
 
 
Reviewer 3’s comment 7 
5.From Figure 1 to Figure 4, you should show statistical value such as p-value. 
Answer to Reviewer 3’s comment 7 
We thank the Reviewer for this comment. We have added this in the Figures. 
 
Reviewer 3’s comment 8 
6.Why did you repeat figure about decline of %FVC in GAP stage Ⅰ ?  How about the figure about decline of 
%FVC in GAP stage stage Ⅱ/Ⅲ ? 
Answer to Reviewer 3’s comment 8 
We thank the Reviewer for this comment. It was a mistake: the first 2 figures pertain to the whole group of 
patients, irrespective of the GAP stage. 
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ABSTRACT 
Background: Real-life data on the use of pirfenidone and nintedanib to treat patients with idiopathic 
pulmonary fibrosis (IPF) are still scarce. 
Methods: We compared the efficacy of either pirfenidone (n=78) or nintedanib (n=28) delivered over a 24-
month period in patients with IPF, followed at two regional clinic centers in Italy, with a group of patients 
who refused the treatment (n=36), and who were considered to be controls.  All patients completed 
regular visits at 1- to 3-month intervals, where primary [forced vital capacity (FVC) and diffusing capacity of 
the lungs for carbon monoxide (DLCO)] and secondary outcomes (side effects, treatment compliance, and 
mortality) were recorded. 
Results: Over time, the decline in FVC and DLCO was significantly higher (p=0.0053 and p=0.037, 
respectively) in controls when compared with the combined treated group, with no significant difference 
between the two treated groups. Compared to patients with less advanced disease (GAP (Gender, Age, 
Physiology) stage I), those in GAP stages II and III showed a significantly higher decline in both FVC and 
DLCO irrespective of the drug taken. Side effects were similarly reported in patients receiving pirfenidone 
and nintedanib (5% and 7%, respectively), whereas mortality did not differ among the three groups. 
Conclusion: This real-life study demonstrated that both pirfenidone and nintedanib were equally effective 
in reducing the decline of FVC and DLCO versus non-treated patients after 24 months of treatment; 
however, patients with more advanced disease were likely to show a more rapid decline in respiratory 
function. 
 




Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, interstitial lung disease of unknown cause, and 
is associated with a high mortality rate [1]. 
In recent years, advances have been made in pharmacotherapeutic approaches to IPF, and two drugs, 
nintedanib and pirfenidone, have been shown to slow down the decline of Forced Vital Capacity (FVC), 
reduce acute exacerbations, and reduce hospitalization for respiratory events [2-6]; however, apart from a 
pooled meta-analyses [7], no study has clearly demonstrated an effect on mortality. More recently, a 
phase-2 double-blind, placebo-controlled study showed that administration of recombinant human 
pentraxin 2 also resulted in a slower decline in lung function over 28 weeks [8]. 
Pirfenidone is an anti-inflammatory and antifibrotic drug that inhibits the synthesis of collagen and reduces 
fibroblast proliferation, whereas nintedanib is a tyrosine kinase inhibitor that targets growth factor 
pathways. Both therapies are costly and may be associated with side effects [3-6]. 
Randomized controlled trials (RCTs) comparing the two drugs are lacking and therefore, prescription of one 
or other of the drugs or the time of initiation of treatment is left to the choice of the clinicians [3]. 
A review published in 2015 about the efficacy of the new treatments for IPF, comparing real-life 
experiences vs randomized clinical trials, concluded that the results from the two different study designs 
seem to be quite different [1]. This is because patients in the real-life scenario often have comorbidities, 
have more severe disease, take concomitant medications, and are likely to have a higher mortality. At the 
time of publication of that review, only real-life data on the use of pirfenidone were available (about 400 
patients) [2–10], whereas since then, more patients using the drug have been enrolled in observational 
studies [11–14], and a few additional patients have been studied using nintedanib [15, 16], or a 
combination of the two drugs [17]. 
To the best of our knowledge, there is only one observational single-center study comparing the clinical 
effects of the two drugs [18], but unfortunately, the data presented for the non- 
Tendering-group were limited to 6 months. 
In our region (Emilia Romagna, Italy), as the local healthcare agency lacked information from RCTs directly 
comparing pirfenidone with nintedanib, the prescribing physician was free to choose between the two 
drugs, according to the patient’s preference and the decision of the doctors. This gave us the possibility to 
compare the real-life efficacy of the two drugs in patients with IPF in two referral centers over a 24-month 
period, and to analyze the data versus a group of patients who refused this treatment, and were therefore 
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PATIENTS AND METHODS 
Informed consent was obtained from each patient before any study activity or treatment was undertaken, 
after having obtained authorization from our Ethics Committee (No. 279/2016). 
Eligible patients were aged 40–80 years at the start of screening,  with IPF diagnosis based on the 
ATS/ERS/JRS/ALAT 2015 guidelines [19]. Patients were naïve to both drugs tested, and most of them had 
received only low doses of oral steroids in the past and/or at the start of this study. 
According to the Italian Health Ministry rules, criteria for starting anti-IPF treatment were percent 
predicted Forced Vital Capacity (FVC %pred.) > 50%, with a Forced Expiratory Volume at one second 
(FEV1)/Forced Vital Capacity ratio>70%, and a percent predicted diffusing capacity of the lung for carbon 
monoxide (DLCO %pred.) >30% at screening. 
Exclusion criteria were: alanine aminotransferase, aspartate aminotransferase or bilirubin levels higher 
than 1.5 times the upper limit of normal; bleeding risk or thrombosis; planned major surgery within the 
next 3 months including lung transplantation, major abdominal, or major intestinal surgery; myocardial 
infarction within the previous 6 months, or unstable angina within the last month. Combined pulmonary 
fibrosis and emphysema (CPFE), defined as the presence of emphysematous lesions in >10% of the affected 
lungs, was also considered as an exclusion criterion. 
In Italy, at least in the first few years (depending on the geographical location) of release of pirfenidone or 
nintedanib, the local health care agency required specific authorization to start the anti-IPF treatment in all 
of the patients. The authorization to prescribe pirfenidone in Italy was officially started in June 2013, while 
nintedanib only became available in June 2016. Based on this, after June 2016, the decision to prescribe 
one of the two drugs was left to the attending physician, based on her/his judgment and the patient’s 
preference. A simple and unbiased leaflet was given to the patient, while the doctor explained the 
mechanism of action, the clinical results, the potential side effects, and the method and timing of 
administration of the two drugs. 
In total, 78 patients were scheduled for pirfenidone treatment and 28 received nintedanib. Pirfenidone 
treatment was started by gradually increasing the dose over a 2-week period from 801 mg daily to 2403 mg 
daily divided into three doses. Nintedanib was started at a dose of 150 mg twice daily, and eventually 
decreased to 100 mg twice daily if not tolerated. Subsequently, patients were followed with regular visits 
to the clinic at 1- to 3-month intervals with full pulmonary function testing, arterial blood gas sampling, 
liver function monitoring, and recording of side effects and treatment compliance. 
 The control group in the study was composed of 36 IPF patients who, after the initial clinical evaluation, 
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decided to refuse the proposed treatment with an anti-IPF drug or who had a contraindication. Specifically, 
13 were not eligible due to DLCO<30% (n=4), elevated age (n=5) or FVC>90% (n=4) (after May 2016, this 
limit was removed by the local health care agency). Eleven patients were not fully convinced about the 
effectiveness of the medication, mainly because of the lack of a clear effect on survival, 6 refused the anti-
IPF treatment because of fear of side effects, 3 were not selected due to elevated levels of alanine 
aminotransferase, aspartate aminotransferase or bilirubin, 2 dropped out after a few weeks (<12 weeks) of 
treatment, and 1 dropped out for an unknown reason.All were enrolled in the follow-up program, which 
was the same as that for all of the other IPF patients undergoing treatment.  Their “chronic” therapy for 
any other comorbidity was left unchanged; symptomatic intervention for dyspnea was prescribed when 
needed (i.e. opioids, high flow nasal cannula or oxygen). 
The primary outcome of this observational, non-sponsored and prospective study was to evaluate the 
trend of lung function parameters (FVC and DLCO) during a 24-month period and to record any side effects. 
Secondary outcomes were the rate of disease progression defined as a reduction in FVC ≥10% of predicted 
and/or diffusion capacity (DLCO) ≥15% of predicted, and the mortality rate at 6, 12, 18, and 24 months. 
Forced Vital Capacity (FVC), percent predicted FVC (FVC%), forced expiratory volume in 1 s (FEV1), percent 
predicted FEV1 (FEV1%), and percent predicted Diffusing Capacity of the Lung for CO (DLCO%) were 
measured using a lung function testing device (JAEGER MasterScreen Body/Diffusion, Vyaire Medical, 
Plymouth, MN, United States). 
The differences between post- and pre-treatment lung function parameters were tested with the Wilcoxon 
signed rank test. Analysis of variance (with Bonferroni test for internal comparison) was used to compare 
groups (i.e. pirfenidone vs nintedanib; and controls (non-treated patients) vs pirfenidone or nintedanib 
(treated group)). 
The changes in FVC% and DLCO% were also analyzed for the two subgroups of patients (stratified by GAP 
(Gender, Age, Physiology) score as stage I or stage II–III). 
The overall survival observed in the cohort was calculated between groups with the log rank test. P values 
<0.05 were considered to be statistically significant. Causes of death were only recorded when this 
occurred in hospital. Telephone interviews were performed regularly to determine whether patients were 
still alive. The causes of death reported by the family or surrogates were not often clear, and these data are 
usually not considered in clinical studies due to lack of reliability. 
The statistical analysis was performed using STATA 11 (Stata-Corp 2009 Stata Statistical Software Release 




In total, 142 patients were included in the study, 78 in the pirfenidone group, 28 in the nintedanib group, 
and 36 in the control, untreated group. Table 1 lists the patients’ characteristics at enrollment, grouped as 
“treated” (i.e. pirfenidone or nintedanib) and control patients. More patients (78 vs 28) were enrolled in 
the pirfenidone group, since that drug was available on the market 2 years before nintedanib. 
Figures 1 and 2 illustrate the primary outcomes of the study. In particular, Figure 1A shows the time course 
of FVC, irrespective of the GAP index, during the 24-month time period. After adjustment for baseline 
differences in FVC, a statistically significant reduction in this parameter was observed in the control group 
during the time period when compared with the combined treated group (p=0.0053). When compared to 
the pirfenidone and nintedanib groups separately, the decline in the controls was statistically significant at 
12 and 24 months (0.027 and 0.011 vs pirfenidone and 0.043 and 0.036 vs nintedanib, respectively). Both 
the baseline value of FVC and the rate of FVC decline over time were not statistically significantly different 
between survivors and non-survivors, irrespective of the groups considered. 
Figure 1B illustrates the time course in the treated groups, irrespective of the GAP index, according to the 
drug taken; no significant difference was observed during the 24-month time course between the 
pirfenidone and nintedanib groups. 
 Changes in DLCO for controls and treated groups are shown in Figure 2A. After adjustment for baseline 
differences in DLCO, non-treated patients showed a statistically significant reduction in this parameter 
(p=0.037). When compared to the pirfenidone and nintedanib groups, the decline in the controls was 
statistically significant at month 24 (0.047 vs pirfenidone and 0.027 vs nintedanib). 
Figure 2B shows that no statistically significant difference was observed between the two treated groups 
and that DLCO remained stable during the 24-month time period. 
The changes in FVC and DLCO were broadly similar over time in the three groups. 
As shown in Figure 3, FVC% stratification of patients using the GAP index at baseline revealed that, 
compared to patients with less advanced disease (GAP stage I, Fig. 3A), those with more advanced disease 
(GAP stages II and III, Fig. 3B) showed a significant decrease over time irrespective of the drug taken and 
without any statistically significant difference between the two groups (overall significance p=0.01). In 
particular, non-treated patients demonstrated a significant decrease in FVC% vs treated GAP stage II–III 
patients at 12 and 24 months (p=0.033 and 0.0040 for pirfenidone, and p=0.047 and 0.0017 for nintedanib, 
respectively). 
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Similar results were obtained for DLCO with the exception of the statistically significant decline in the 
control group in both GAP I and GAP II–III subsets of patients (p=0.018 and 0.0067, respectively). 
Figure 4 shows the percentage of patients with a reduction in FVC >10% at 6, 12, and 24 months. Both 
drugs (pirfenidone and nintedanib) statistically significantly and similarly reduced this decrease vs no 
treatment, but with no significant difference between pirfenidone and nintedanib. 
 
Most of the patients tolerated the treatments well and the dropout rate was 4/78 (5%) for pirfenidone and 
2/28 (7%) for nintedanib. Side effects are listed in Table 2,  and no statistically significant difference was 
observed between the two treatments. 
In the whole patient cohort, a total of 55/142 (39%) patients died in the 24-month period. In the control 
group, mortality from all causes was 44% (16/36 patients), compared with 37% (29/78 patients) of those 
patients treated with pirfenidone, and 36% (10/28 patients) of those treated with nintedanib. Table 3 
shows the causes of death of the hospitalized patients in the three groups. Data recorded during the 
telephone interviews were not considered reliable.  The occurrence of lung tumors was 4/36 (11%), 5/78 
(6.4%), and 1/28 (3.5%) for the control, pirfenidone, and nintedanib groups, respectively; however, there 





In the present observational investigation, we have demonstrated that both pirfenidone and nintedanib are 
equally effective in reducing the decline of FVC and DLCO versus non-treated patients over a 24-month 
period; however, patients with more advanced disease (i.e. those in GAP stages II and III) were likely to 
show a more rapid decline in respiratory function. Among the secondary outcomes, side effects were 
similar in patients receiving the anti-IPF treatments, whereas mortality rates did not differ among the three 
groups. 
The present study is unique in that it compares the pulmonary function and survival rate not only in the 
two groups of patients receiving either pirfenidone or nintedanib, but also in a relatively large control 
group of individuals who, for various reasons, refused to be treated, despite the fact that they met the 
inclusion criteria for both drugs. This investigation also shows that a relatively high number of the non-
treated patients (>20% if we exclude those patients with elevated levels of alanine aminotransferase, 
aspartate aminotransferase or bilirubin) refused to undergo one of the two proposed treatments, mainly 
because they were dissuaded by the possible side effects or were not fully convinced of the efficacy of the 
drugs, some of them after having received the opinion of their family doctor. 
These results highlight the importance of improving the educational models (i.e. with a dedicated website, 
training and education of general practitioners), to convince the more skeptical patients about the safety 
and efficacy of the available treatments. 
As for all of the RCTs, rigorous inclusion and exclusion criteria were applied per protocol when assessing the 
efficacy of pirfenidone or nintedanib, so that many patients who were potential candidates for treatment 
were excluded. Just as an example, 37% and 44% of the patients screened for two RCTs assessing the 
efficacy of nintedanib and pirfenidone, respectively, were not enrolled [20, 24]. 
Clearly, all these exclusion criteria were not applied by the regulatory agencies of European countries, so 
that, as described by Harari and Caminati in their review [1], in real-life studies, comorbidities were 
frequent, particularly overweight/obesity and pulmonary hypertension. Indeed, the stages of the disease, 
as assessed with the GAP index were different. 
To our knowledge, there is only one single-center study comparing the 6-month outcomes of IPF patients 
undergoing treatment with pirfenidone or placebo [23], but this very short timeframe did not allow the 
authors to reach a firm conclusion; indeed, a control group was lacking. 
Our study demonstrated once more that both pirfenidone and nintedanib significantly slowed disease 
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progression, as assessed by the decline in FVC and DLCO. Our results are also in line with RCTs and real-life 
observational studies that showed a favorable safety profile and generally good tolerance of both drugs 
over the long term. Indeed, to our knowledge, this is the first long-term direct comparison between the 
two available treatments for IPF, and confirms what has already been suggested in the literature, that both 
drugs are equally effective in reducing the functional decline. 
Interestingly, earlier observational studies with nintedanib enrolled patients with more advanced disease 
than those in the present study (FVC ≤ 50% and/or DLCO ≤ 35%), so that our study expands our knowledge 
on individuals with less severe IPF. This allowed us to compare the two drugs in patients with similar stages 
of disease. 
As also demonstrated by several earlier investigations, the rate of decline of FVC or DLCO was higher in 
patients with more advanced disease, even when they were undergoing therapy [7, 25, 26], and therefore 
it is important to identify IPF patients in the early stage of their disease, and in whom treatment may be 
more successful in slowing down the progression of the disease. 
This is also the first study to assess the mortality rate in patients treated with either pirfenidone or 
nintedanib, and with the rate in an untreated control group. A recent retrospective analysis of 379 Italian 
patients treated with pirfenidone demonstrated that the decline in FVC and the safety profile were 
consistent with findings observed in Phase III pirfenidone clinical trials and with similar side effects 
compared with our study [27]. 
In our cohort, the 24-month mortality rate was not statistically significantly different among the groups, 
despite the fact that survival was somehow higher in the controls. As already stated, only a meta-analysis 
was able to demonstrate a survival improvement vs placebo using pirfenidone [20], but this had the 
obvious limitations of such kinds of investigation.  We were not able to record all of the causes of mortality 
in all of our patients, since most died in hospitals, while others died at home, thus making it difficult to 
assess the real cause of death. The hospital deaths were mainly, but not exclusively, due to respiratory 
failure which may or may not have been the result of acute exacerbations, since other significant causes of 
death were cardiac problems or tumors. Thus, the recording of FVC in these patients was probably not the 
best indicator of mortality. 
Our study has several major limitations. First, it was not a randomized controlled trial; however, at this 
time, we are not aware of any ongoing study enrolling three arms of patients (placebo, pirfenidone, and 
nintedanib), so it may be considered novel and original, being the first one, despite being non-randomized. 
Indeed, our ethics committee felt that it would be unethical to approve a placebo arm, considering the 
favorable results already available on pulmonary function in patients treated with both drugs. 
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Second,  we did not perform a sample size calculation based on primary outcome, and the study population 
was relatively small and non-homogeneous among the groups. It was not possible to improve sample size 
and homogeneity because of the different timing of approval of the two active drugs; however, the number 
of patients enrolled was in keeping with most of the real-life studies reported, in which, very rarely, a 
threshold of 100 patients was achieved. 
In conclusion, our real-life study demonstrated for the first time that both pirfenidone and nintedanib are 
equally effective in reducing the decline of FVC and DLCO in a 24-month period compared with non-treated 
patients. Patients with more advanced disease were likely to show a more rapid decline in respiratory 
function. The mortality rate was similar in the treated and non-treated groups, but this trial was not 
randomized. Notwithstanding this, our findings may launch the call for a large multicenter, randomized trial 








Legend to Figures 
 
Figure 1. Time course of FVC over 24 months showing the trend in the whole population, comparing the 
three study groups (panel A) and the two treatment groups (nintedanib and pirfenidone) (panel B). 
 
Figure 2. Time course of DLCO over 24 months showing the trend in the whole population comparing the 
three study groups (panel A) and the two treatment groups (nintedanib and pirfenidone) (panel B). 
 
Figure 3. Time course of FVC over 24 months in the three study groups divided according to GAP I (panel A) 
and GAP II–III (panel B) score. 
 
Figure 4. Proportion of patients in the three study groups showing a decline in FVC >10% from baseline 
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ABSTRACT 
Background: Real-life data on the use of pirfenidone and nintedanib to treat patients with idiopathic 
pulmonary fibrosis (IPF) are still scarce. 
Methods: We compared the efficacy of either pirfenidone (n=78) or nintedanib (n=28) delivered over a 24-
month period in patients with IPF, followed at two regional clinic centers in Italy, with a group of patients 
who refused the treatment (n=36), and who were considered to be controls. All patients completed regular 
visits at 1- to 3-month intervals, where primary [forced vital capacity (FVC) and diffusing capacity of the 
lungs for carbon monoxide (DLCO)] and secondary outcomes (side effects, treatment compliance, and 
mortality) were recorded. All patients completed regular visits at 1- to 3-month intervals, where primary 
[forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO)] and secondary 
outcomes (side effects, treatment compliance, and mortality) were recorded. 
Results: Over time, the decline in FVC and DLCO was significantly higher (p=0.0053 and p=0.037, 
respectively) in controls when compared with the combined treated group, with no significant difference 
between the two treated groups. Compared to patients with less advanced disease (GAP (Gender, Age, 
Physiology) stage I), those in GAP stages II and III showed a significantly higher decline in both FVC and 
DLCO irrespective of the drug taken. Side effects were similarly reported in patients receiving pirfenidone 
and nintedanib (5% and 7%, respectively), whereas mortality did not differ among the three groups. 
Conclusion: This real-life study demonstrated that both pirfenidone and nintedanib were equally effective 
in reducing the decline of FVC and DLCO versus non-treated patients after 24 months of treatment; 
however, patients with more advanced disease were likely to show a more rapid decline in respiratory 
function. 
 
Keywords: Idiopathic pulmonary fibrosis, forced vital capacity, nintedanib, pirfenidone 
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INTRODUCTION 
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, interstitial lung disease of unknown cause, and 
is associated with a high mortality rate [1]. 
In recent years, advances have been made in pharmacotherapeutic approaches to IPF, and two drugs, 
nintedanib and pirfenidone, have been shown to slow down the decline of Forced Vital Capacity (FVC), 
reduce acute exacerbations, and reduce hospitalization for respiratory events [2-6]; however, apart from a 
pooled meta-analyses [7], no study has clearly demonstrated an effect on mortality. More recently, a 
phase-2 double-blind, placebo-controlled study showed that administration of recombinant human 
pentraxin 2 also resulted in a slower decline in lung function over 28 weeks [8]. 
Pirfenidone is an anti-inflammatory and antifibrotic drug that inhibits the synthesis of collagen and reduces 
fibroblast proliferation, whereas nintedanib is a tyrosine kinase inhibitor that targets growth factor 
pathways. Both therapies are costly and may be associated with side effects [3-6]. 
Randomized controlled trials (RCTs) comparing the two drugs are lacking and therefore, prescription of one 
or other of the drugs or the time of initiation of treatment is left to the choice of the clinicians [3]. 
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, interstitial lung disease of unknown cause, and 
is associated with a high mortality rate [1]. 
In recent years, advances have been made in pharmacotherapeutic approaches to IPF, and two drugs, 
nintedanib and pirfenidone, have been shown to slow down the decline of Forced Vital Capacity (FVC), 
reduce acute exacerbations, and reduce hospitalization for respiratory events [2-6]; however, apart from a 
pooled meta-analyses [7], no study has clearly demonstrated an effect on mortality. More recently, a 
phase-2 double-blind, placebo-controlled study showed that administration of recombinant human 
pentraxin 2 also resulted in a slower decline in lung function over 28 weeks [8]. 
Pirfenidone is an anti-inflammatory and antifibrotic drug that inhibits the synthesis of collagen and reduces 
fibroblast proliferation, whereas nintedanib is a tyrosine kinase inhibitor that targets growth factor 
pathways. Both therapies are costly and may be associated with side effects [3-6]. 
Randomized controlled trials (RCTs) comparing the two drugs are lacking and therefore, prescription of one 
or other of the drugs or the time of initiation of treatment is left to the choice of the clinicians [3]. 
A review published in 2015 about the efficacy of the new treatments for IPF, comparing real-life 
experiences vs randomized clinical trials, concluded that the results from the two different study designs 
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seem to be quite different [1]. This is because patients in the real-life scenario often have comorbidities, 
have more severe disease, take concomitant medications, and are likely to have a higher mortality. At the 
time of publication of that review, only real-life data on the use of pirfenidone were available (about 400 
patients) [2–10], whereas since then, more patients using the drug have been enrolled in observational 
studies [11–14], and a few additional patients have been studied using nintedanib [15, 16], or a 
combination of the two drugs [17]. 
To the best of our knowledge, there is only one observational single-center study comparing the clinical 
effects of the two drugs [18], but unfortunately, the data presented for the non- 
Tendering-group were limited to 6 months. 
In our region (Emilia Romagna, Italy), as the local healthcare agency lacked information from RCTs directly 
comparing pirfenidone with nintedanib, the prescribing physician was free to choose between the two 
drugs, according to the patient’s preference and the decision of the doctors. This gave us the possibility to 
compare the real-life efficacy of the two drugs in patients with IPF in two referral centers over a 24-month 
period, and to analyze the data versus a group of patients who refused this treatment, and were therefore 




Formatted: Right:  0.63 cm
 
PATIENTS AND METHODS 
Informed consent was obtained from each patient before any study activity or treatment was undertaken, 
after having obtained authorization from our Ethics Committee (No. 227985/2016). 
Eligible patients were aged 40–80 years at the start of screening, with IPF diagnosis based on the 
ATS/ERS/JRS/ALAT 2015 guidelines [19]. Patients were naïve to both drugs tested, and most of them had 
received only low doses of oral steroids in the past and/or at the start of this study. with IPF diagnosis 
based on the ATS/ERS/JRS/ALAT 2015 guidelines [19]. Patients were naïve to both drugs tested, and most 
of them had received only low doses of oral steroids in the past and/or at the start of this study. 
According to the Italian Health Ministry rules, criteria for starting anti-IPF treatment were criteria for 
starting anti-IPF treatment were percent predicted Forced Vital Capacity (FVC %pred.) > 50%, with a Forced 
Expiratory Volume at one second (FEV1)/Forced Vital Capacity ratio>70%, and a percent predicted diffusing 
capacity of the lung for carbon monoxide (DLCO %pred.) >30% at screening. 
Exclusion criteria were: alanine aminotransferase, aspartate aminotransferase or bilirubin levels higher 
than 1.5 times the upper limit of normal; bleeding risk or thrombosis; planned major surgery within the 
next 3 months including lung transplantation, major abdominal, or major intestinal surgery; myocardial 
infarction within the previous 6 months, or unstable angina within the last month. Combined pulmonary 
fibrosis and emphysema (CPFE), defined as the presence of emphysematous lesions in >10% of the affected 
lungs, was also considered as an exclusion criterion. 
In Italy, at least in the first few years (depending on the geographical location) of release of pirfenidone or 
nintedanib, the local health care agency required specific authorization to start the anti-IPF treatment in all 
of the patients. In Italy, at least in the first few years (depending on the geographical location) of release of 
pirfenidone or nintedanib, the local health care agency required specific authorization to start the anti-IPF 
treatment in all of the patients. The authorization to prescribe pirfenidone in Italy was officially started in 
June 2013, while nintedanib only became available in June 2016. Based on this, after June 2016, the 
decision to prescribe one of the two drugs was left to the attending physician, based on her/his judgment 
and the patient’s preference. A simple and unbiased leaflet was given to the patient, while the doctor 
explained the mechanism of action, the clinical results, the potential side effects, and the method and 
timing of administration of the two drugs. 
In total, 78 patients were scheduled for pirfenidone treatment and 28 received nintedanib. Pirfenidone 
treatment was started by gradually increasing the dose over a 2-week period from 801 mg daily to 2403 mg 
daily divided into three doses. Nintedanib was started at a dose of 150 mg twice daily, and eventually 
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decreased to 100 mg twice daily if not tolerated. Subsequently, patients were followed with regular visits 
to the clinic at 1- to 3-month intervals with full pulmonary function testing, arterial blood gas sampling, 
liver function monitoring, and recording of side effects and treatment compliance. 
The control group in the study was composed of 36 IPF patients who, after the initial clinical evaluation, 
decided to refuse the proposed treatment with an anti-IPF drug or who had a contraindication The control 
group in the study was composed of 36 IPF patients who, after the initial clinical evaluation, decided to 
refuse the proposed treatment with an anti-IPF drug or who had a contraindication. Specifically, 13 were 
not eligible due to DLCO<30% (n=4), elevated age (n=5) or FVC>90% (n=4) (after May 2016, this limit was 
removed by the local health care agency). Eleven patients were not fully convinced about the effectiveness 
of the medication, mainly because of the lack of a clear effect on survival, 6 refused the anti-IPF treatment 
because of fear of side effects, 3 were not selected due to elevated levels of alanine aminotransferase, 
aspartate aminotransferase or bilirubin, 2 dropped out after a few weeks (<12 weeks) of treatment, and 1 
dropped out for an unknown reason. Eleven patients were not fully convinced about the effectiveness of 
the medication, mainly because of the lack of a clear effect on survival, 6 refused the anti-IPF treatment 
because of fear of side effects, 3 were not selected due to elevated levels of alanine aminotransferase, 
aspartate aminotransferase or bilirubin, 2 dropped out after a few weeks (<12 weeks) of treatment, and 1 
dropped out for an unknown reason.All were enrolled in the follow-up program, which was the same as 
that for all of the other IPF patients undergoing treatment. Their “chronic” therapy for any other 
comorbidity was left unchanged; symptomatic intervention for dyspnea was prescribed when needed (i.e. 
opioids, high flow nasal cannula or oxygen). Their “chronic” therapy for any other comorbidity was left 
unchanged; symptomatic intervention for dyspnea was prescribed when needed (i.e. opioids, high flow 
nasal cannula or oxygen). 
The primary outcome of this observational, non-sponsored and prospective study was to evaluate the 
trend of lung function parameters (FVC and DLCO) during a 24-month period and to record any side effects. 
Secondary outcomes were the rate of disease progression defined as a reduction in FVC ≥10% of predicted 
and/or diffusion capacity (DLCO) ≥15% of predicted, and the mortality rate at 6, 12, 18, and 24 months. 
Forced Vital Capacity (FVC), percent predicted FVC (FVC%), forced expiratory volume in 1 s (FEV1), percent 
predicted FEV1 (FEV1%), and percent predicted Diffusing Capacity of the Lung for CO (DLCO%) were 
measured using a lung function testing device (JAEGER MasterScreen Body/Diffusion, Vyaire Medical, 
Plymouth, MN, United States). 
The differences between post- and pre-treatment lung function parameters were tested with the Wilcoxon 
signed rank test. Analysis of variance (with Bonferroni test for internal comparison) was used to compare 
groups (i.e. pirfenidone vs nintedanib; and controls (non-treated patients) vs pirfenidone or nintedanib 
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(treated group)). 
The changes in FVC% and DLCO% were also analyzed for the two subgroups of patients (stratified by GAP 
(Gender, Age, Physiology) score as stage I or stage II–III). 
The overall survival observed in the cohort was calculated between groups with the log rank test. P values 
<0.05 were considered to be statistically significant. Causes of death were only recorded when this 
occurred in hospital. Telephone interviews were performed regularly to determine whether patients were 
still alive. The causes of death reported by the family or surrogates were not often clear, and these data are 
usually not considered in clinical studies due to lack of reliability. 
The overall survival observed in the cohort was calculated between groups with the log rank test. P values 
<0.05 were considered to be statistically significant. Causes of death were only recorded when this 
occurred in hospital. Telephone interviews were performed regularly to determine whether patients were 
still alive. The causes of death reported by the family or surrogates were not often clear, and these data are 
usually not considered in clinical studies due to lack of reliability. 
The statistical analysis was performed using STATA 11 (Stata-Corp 2009 Stata Statistical Software Release 
11; StataCorp LP, College Station, TX, USA). 
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RESULTS 
In total, 142 patients were included in the study, 78 in the pirfenidone group, 28 in the nintedanib group, 
and 36 in the control, untreated group. Table 1 lists the patients’ characteristics at enrollment, grouped as 
“treated” (i.e. pirfenidone or nintedanib) and control patients. More patients (78 vs 28) were enrolled in 
the pirfenidone group, since that drug was available on the market 2 years before nintedanib. 
Figures 1 and 2 illustrate the primary outcomes of the study. In particular, Figure 1A shows the time course 
of FVC, irrespective of the GAP index, during the 24-month time period. Figures 1 and 2 illustrate the 
primary outcomes of the study. In particular, Figure 1A shows the time course of FVC, irrespective of the 
GAP index, during the 24-month time period. After adjustment for baseline differences in FVC, a statistically 
significant reduction in this parameter was observed in the control group during the time period when 
compared with the combined treated group (p=0.0053). When compared to the pirfenidone and 
nintedanib groups separately, the decline in the controls was statistically significant at 12 and 24 months 
(0.027 and 0.011 vs pirfenidone and 0.043 and 0.036 vs nintedanib, respectively). Both the baseline value 
of FVC and the rate of FVC decline over time were not statistically significantly different between survivors 
and non-survivors, irrespective of the groups considered. Both the baseline value of FVC and the rate of 
FVC decline over time were not statistically significantly different between survivors and non-survivors, 
irrespective of the groups considered. 
Figure 1B illustrates the time course in the treated groups, irrespective of the GAP index, according to the 
drug taken; no significant difference was observed during the 24-month time course between the 
pirfenidone and nintedanib groups. 
Changes in DLCO for controls and treated groups are shown in Figure 2A Changes in DLCO for controls and 
treated groups are shown in Figure 2A. After adjustment for baseline differences in DLCO, non-treated 
patients showed a statistically significant reduction in this parameter (p=0.037). When compared to the 
pirfenidone and nintedanib groups, the decline in the controls was statistically significant at month 24 
(0.047 vs pirfenidone and 0.027 vs nintedanib). 
Figure 2B shows that no statistically significant difference was observed between the two treated groups 
and that DLCO remained stable during the 24-month time period. 
The changes in FVC and DLCO were broadly similar over time in the three groups. 
The changes in FVC and DLCO were broadly similar over time in the three groups. 
As shown in Figure 3 Figure 3, FVC% stratification of patients using the GAP index at baseline revealed that, 
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compared to patients with less advanced disease (GAP stage I, Fig. 3A Fig. 3A), those with more advanced 
disease (GAP stages II and III, Fig. 3B Fig. 3B) showed a significant decrease over time irrespective of the 
drug taken and without any statistically significant difference between the two groups (overall significance 
p=0.01overall significance p=0.01). In particular, non-treated patients demonstrated a significant decrease 
in FVC% vs treated GAP stage II–III GAP stage II–III patients at 12 and 24 months (p=0.033 and 0.0040 for 
pirfenidone, and p=0.047 and 0.0017 for nintedanib, respectively). 
Similar results were obtained for DLCO with the exception of the statistically significant decline in the 
control group in both GAP I and GAP II–III subsets of patients (p=0.018 and 0.0067, respectively). 
Figure 4 shows the percentage of patients with a reduction in FVC >10% at 6, 12, and 24 months. Both 
drugs (pirfenidone and nintedanibpirfenidone and nintedanib) statistically significantly and similarly 
reduced this decrease vs no treatment no treatment, but with no significant difference between 
pirfenidone and nintedanib. 
 
Most of the patients tolerated the treatments well and the dropout rate was 4/78 (5%) for pirfenidone and 
2/28 (7%) for nintedanib. Side effects are listed in Table 2, and no statistically significant difference was 
observed between the two treatments. and no statistically significant difference was observed between the 
two treatments. 
In the whole patient cohort, a total of 55/142 (39%) patients died in the 24-month period. In the control 
group, mortality from all causes was 44% (16/36 patients), compared with 37% (29/78 patients) of those 
patients treated with pirfenidone, and 36% (10/28 patients) of those treated with nintedanib. Table 3 
shows the causes of death of the hospitalized patients in the three groups. Data recorded during the 
telephone interviews were not considered reliable. The occurrence of lung tumors was 4/36 (11%), 5/78 
(6.4%), and 1/28 (3.5%) for the control, pirfenidone, and nintedanib groups, respectively; however, there 
were no statistically significant differences between the results (p=0.5). The occurrence of lung tumors was 
4/36 (11%), 5/78 (6.4%), and 1/28 (3.5%) for the control, pirfenidone, and nintedanib groups, respectively; 
however, there were no statistically significant differences between the results (p=0.5). 
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DISCUSSION 
In the present observational investigation, we have demonstrated that both pirfenidone and nintedanib are 
equally effective in reducing the decline of FVC and DLCO versus non-treated patients over a 24-month 
period; however, patients with more advanced disease (i.e. those in GAP stages II and III) were likely to 
show a more rapid decline in respiratory function. Among the secondary outcomes, side effects were 
similar in patients receiving the anti-IPF treatments, whereas mortality rates did not differ among the three 
groups. 
The present study is unique in that it compares the pulmonary function and survival rate not only in the 
two groups of patients receiving either pirfenidone or nintedanib, but also in a relatively large control 
group of individuals who, for various reasons, refused to be treated, despite the fact that they met the 
inclusion criteria for both drugs. This investigation also shows that a relatively high number of the non-
treated patients (>20% if we exclude those patients with elevated levels of alanine aminotransferase, 
aspartate aminotransferase or bilirubin) refused to undergo one of the two proposed treatments, mainly 
because they were dissuaded by the possible side effects or were not fully convinced of the efficacy of the 
drugs, some of them after having received the opinion of their family doctor. 
These results highlight the importance of improving the educational models (i.e. with a dedicated website, 
training and education of general practitioners), to convince the more skeptical patients about the safety 
and efficacy of the available treatments. 
As for all of the RCTs, rigorous inclusion and exclusion criteria were applied per protocol when assessing the 
efficacy of pirfenidone or nintedanib, so that many patients who were potential candidates for treatment 
were excluded. Just as an example, 37% and 44% of the patients screened for two RCTs assessing the 
efficacy of nintedanib and pirfenidone, respectively, were not enrolled [20, 24]. 
Clearly, all these exclusion criteria were not applied by the regulatory agencies of European countries, so 
that, as described by Harari and Caminati in their review [1], in real-life studies, comorbidities were 
frequent, particularly overweight/obesity and pulmonary hypertension. Indeed, the stages of the disease, 
as assessed with the GAP index were different. 
In the present observational investigation, we have demonstrated that both pirfenidone and nintedanib are 
equally effective in reducing the decline of FVC and DLCO versus non-treated patients over a 24-month 
period; however, patients with more advanced disease (i.e. those in GAP stages II and III) were likely to 
show a more rapid decline in respiratory function. Among the secondary outcomes, side effects were 
similar in patients receiving the anti-IPF treatments, whereas mortality rates did not differ among the three 
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groups. 
The present study is unique in that it compares the pulmonary function and survival rate not only in the 
two groups of patients receiving either pirfenidone or nintedanib, but also in a relatively large control 
group of individuals who, for various reasons, refused to be treated, despite the fact that they met the 
inclusion criteria for both drugs. This investigation also shows that a relatively high number of the non-
treated patients (>20% if we exclude those patients with elevated levels of alanine aminotransferase, 
aspartate aminotransferase or bilirubin) refused to undergo one of the two proposed treatments, mainly 
because they were dissuaded by the possible side effects or were not fully convinced of the efficacy of the 
drugs, some of them after having received the opinion of their family doctor. 
These results highlight the importance of improving the educational models (i.e. with a dedicated website, 
training and education of general practitioners), to convince the more skeptical patients about the safety 
and efficacy of the available treatments. 
As for all of the RCTs, rigorous inclusion and exclusion criteria were applied per protocol when assessing the 
efficacy of pirfenidone or nintedanib, so that many patients who were potential candidates for treatment 
were excluded. Just as an example, 37% and 44% of the patients screened for two RCTs assessing the 
efficacy of nintedanib and pirfenidone, respectively, were not enrolled [20, 24]. 
Clearly, all these exclusion criteria were not applied by the regulatory agencies of European countries, so 
that, as described by Harari and Caminati in their review [1], in real-life studies, comorbidities were 
frequent, particularly overweight/obesity and pulmonary hypertension. Indeed, the stages of the disease, 
as assessed with the GAP index were different. 
To our knowledge, there is only one single-center study comparing the 6-month outcomes of IPF patients 
undergoing treatment with pirfenidone or placebo [23], but this very short timeframe did not allow the 
authors to reach a firm conclusion; indeed, a control group was lacking. 
Our study demonstrated once more that both pirfenidone and nintedanib significantly slowed disease 
progression, as assessed by the decline in FVC and DLCO. Our results are also in line with RCTs and real-life 
observational studies that showed a favorable safety profile and generally good tolerance of both drugs 
over the long term. Indeed, to our knowledge, this is the first long-term direct comparison between the 
two available treatments for IPF, and confirms what has already been suggested in the literature, that both 
drugs are equally effective in reducing the functional decline. 
Interestingly, earlier observational studies with nintedanib enrolled patients with more advanced disease 
than those in the present study (FVC ≤ 50% and/or DLCO ≤ 35%), so that our study expands our knowledge 
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on individuals with less severe IPF. This allowed us to compare the two drugs in patients with similar stages 
of disease. 
As also demonstrated by several earlier investigations, the rate of decline of FVC or DLCO was higher in 
patients with more advanced disease, even when they were undergoing therapy [7, 25, 26], and therefore 
it is important to identify IPF patients in the early stage of their disease, and in whom treatment may be 
more successful in slowing down the progression of the disease. 
This is also the first study to assess the mortality rate in patients treated with either pirfenidone or 
nintedanib, and with the rate in an untreated control group. A recent retrospective analysis of 379 Italian 
patients treated with pirfenidone demonstrated that the decline in FVC and the safety profile were 
consistent with findings observed in Phase III pirfenidone clinical trials and with similar side effects 
compared with our study [27]. 
As also demonstrated by several earlier investigations, the rate of decline of FVC or DLCO was higher in 
patients with more advanced disease, even when they were undergoing therapy [7, 25, 26], and therefore 
it is important to identify IPF patients in the early stage of their disease, and in whom treatment may be 
more successful in slowing down the progression of the disease. 
This is also the first study to assess the mortality rate in patients treated with either pirfenidone or 
nintedanib, and with the rate in an untreated control group. A recent retrospective analysis of 379 Italian 
patients treated with pirfenidone demonstrated that the decline in FVC and the safety profile were 
consistent with findings observed in Phase III pirfenidone clinical trials and with similar side effects 
compared with our study [27]. 
In our cohort, the 24-month mortality rate was not statistically significantly different among the groups, 
despite the fact that survival was somehow higher in the controls. As already stated, only a meta-analysis 
was able to demonstrate a survival improvement vs placebo using pirfenidone [20], but this had the 
obvious limitations of such kinds of investigation. We were not able to record all of the causes of mortality 
in all of our patients, since most died in hospitals, while others died at home, thus making it difficult to 
assess the real cause of death. The hospital deaths were mainly, but not exclusively, due to respiratory 
failure which may or may not have been the result of acute exacerbations, since other significant causes of 
death were cardiac problems or tumors. Thus, the recording of FVC in these patients was probably not the 
best indicator of mortality. We were not able to record all of the causes of mortality in all of our patients, 
since most died in hospitals, while others died at home, thus making it difficult to assess the real cause of 
death. The hospital deaths were mainly, but not exclusively, due to respiratory failure which may or may 
not have been the result of acute exacerbations, since other significant causes of death were cardiac 
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problems or tumors. Thus, the recording of FVC in these patients was probably not the best indicator of 
mortality. 
Our study has several major limitations. First, it was not a randomized controlled trial; however, at this 
time, we are not aware of any ongoing study enrolling three arms of patients (placebo, pirfenidone, and 
nintedanib), so it may be considered novel and original, being the first one, despite being non-randomized. 
Indeed, our ethics committee felt that it would be unethical to approve a placebo arm, considering the 
favorable results already available on pulmonary function in patients treated with both drugs. 
Second, we did not perform a sample size calculation based on primary outcome we did not perform a 
sample size calculation based on primary , and the study population was relatively small outcome, and the 
study population was relatively small and non-homogeneous among the groups. It was not possible to 
improve sample size and homogeneity because of the different timing of approval of the two active drugs; 
however, the number of patients enrolled was in keeping with most of the real-life studies reported, in 
which, very rarely, a threshold of 100 patients was achieved. 
In conclusion, our real-life study demonstrated for the first time that both pirfenidone and nintedanib are 
equally effective in reducing the decline of FVC and DLCO in a 24-month period compared with non-treated 
patients. Patients with more advanced disease were likely to show a more rapid decline in respiratory 
function. The mortality rate was similar in the treated and non-treated groups, but this trial was not 
randomized. Notwithstanding this, our findings may launch the call for a large multicenter, randomized trial 
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Legend to Figures 
 
Figure 1. Time course of FVC over 24 months showing the trend in the whole population, comparing the 
three study groups (panel A) and the two treatment groups (nintedanib and pirfenidone) (panel B). 
 
Figure 2. Time course of DLCO over 24 months showing the trend in the whole population comparing the 
three study groups (panel A) and the two treatment groups (nintedanib and pirfenidone) (panel B). 
 
Figure 3. Time course of FVC over 24 months in the three study groups divided according to GAP I (panel A) 
and GAP II–III (panel B) score. 
 
Figure 4. Proportion of patients in the three study groups showing a decline in FVC >10% from baseline 
after 6, 12, and 24 months. 
Figure 1. Time course of FVC over 24 months showing the trend in the whole population, comparing the 
three study groups (panel A) and the two treatment groups (nintedanib and pirfenidone) (panel B). 
 
Figure 2. Time course of DLCO over 24 months showing the trend in the whole population comparing the 
three study groups (panel A) and the two treatment groups (nintedanib and pirfenidone) (panel B). 
 
Figure 3. Time course of FVC over 24 months in the three study groups divided according to GAP I (panel A) 
and GAP II–III (panel B) score. 
 
Figure 4. Proportion of patients in the three study groups showing a decline in FVC >10% from baseline 
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 Pirfenidone and nintedanib are the mostly used anti-fibrotic drugs for idiopathic pulmonary 
fibrosis (IPF) 
 
 Face to face, randomized controlled and real life studies are lacking 
 
 
  In this real life study, both drugs were effective in reducing the decline of Forced Vital 
Capacity  and Diffusing Lung Capacity versus non-treated patients at 24-month 
 




 Total of patients Pirfenidone Nintedanib No treatment P 
Patients, n 142 78 28 36  
Male, n (%) 113 (78%) 64 (82%) 22 (78%) 27 (75%) 0.7 
Age, years (SD) 73,3 (9) 73 (8) 72 (7) 75 (7) 0.25 
Current or former 
smokers, n (%) 
118 (82%) 65 (83%) 24 (85%) 29 (80%) 0.8 
FVC, %pred (SD) 80.9 (17.7) 75 (17) 84 (16) 87 (18) 0.01 
DLCO, %pred (SD) 53 (16.3) 50 (13) 45 (19) 55 (15) 0.029 
GAP Index II-III, n (%) 71 (50%) 41 (53%) 15 (54%) 15 (43%) 0.5 
GERD, n (%) 61 (43%) 34 (43%) 12 (44%) 15 (43%) 0.9 
Cardiovascular 
comorbidities, n (%) 
69 (48%) 37 (48%) 12 (44%) 20 (56%) 0.6 
Dyspnea at baseline, 
Borg score (SD) 
2.13 (1.6) 1.95 (1.9) 2.54 (2.12) 2.23 (1.04) 0.3 
Presence of cough, n 
(%) 
92 (64.7%) 50 (64%)* 18 (64%)** 24 (66%) *** 0.9 




Table 1  
Patients’ characteristics at enrollment, divided as “treated” (i.e. pirfenidone or nintedanib) and control. 
Legend. FVC= Forced Vital Capacity. DLCO= Lung Tissue Diffuse for Carbon Dioxide. GAP Index = Gender, Age and Physiology 


















Pirfenidone Nintedanib No treatment 
Total, n (%) 
26 (33%) 13 (46%) 5 (14%) 
Diarrhea, n (%) 0 (0%) 9 (32%) 2 (5%) 
Nausea, n (%) 3 (4%) 0 (0%) 2 (5%) 
Dyspepsia, n (%) 12 (15%) 0 (0%) 0 (0%) 
Headache, n (%) 0 (0%) 0 (0%) 1 (3%) 
Involuntary weight loss, n (%) 0 (0%) 4 (14%) 0 (0%) 
Transaminase elevation, n (%) 0 (0%) 3 (11%) 0 (0%) 
Loss of appetite, n (%) 3 (4%) 0 (0%) 0 (0%) 
Phototoxic reactions, n (%) 4 (5%) 0 (0%) 0 (0%) 
Difficulty in concentration, n (%) 4 (5%) 0 (0%) 0 (0%) 
 
Table 2 
Side effects in the 3 groups of patients.  






Death cause  Pirfenidone (32) Nintedanib (8) No treatment (18) 
Acute respiratory failure, n (%)  18  (56%) 5 (62%) 11 (61%) 
Lung cancer  2 (6%) 0 (0%) 3 (17%) 
Lung infection  2 (6%) 0 (0%) 3 (17%) 
Stroke  2 (6%) 0 (0%) 0 (0%) 
Acute hearth disease   4 (12%) 0 (0%) 0 (0%) 
Liver failure  0 (0%) 2 (25%) 0 (0%) 
Cancer other than lung  3 (9%) 1 (13%) 1 (6%) 
Post surgical complications  1 (3%) 0 (0%) 0 (0%) 
 
Table 3 





































































Legend to figures 
 
Figure 1- Time course of FVC over 24 month. Trend in the whole population comparing the 
three study groups (panel A) and the two groups of treatment (nintedanib and pirfinidone) 
(panel B). 
 
Figure 2- Time course of DLCO over 24 month. Trend in the whole population comparing 
the three study groups (panel A) and the two groups of treatment (nintedanib and 
pirfinidone) (panel B). 
 
Figure 3- Time course of FVC over 24 month in the three study groups divided according 
to the GAP I (panel A) and GAP II-III (panel B) score. 
 
Figure 4- Proportion of patients in the three groups showing a decline in FVC >10% from 
baseline after 6, 12, and 24 months. 
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